Tetrabenazine in the Treatment of Huntington's Disease

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2009 Apr 22

PMID 19381278

Citations 31

Authors

Diana Paleacu

Affiliations

Soon will be listed here.

Abstract

Tetrabenazine (TBZ), a catecholamine-depleting agent initially developed for the treatment of schizophrenia, when tested for other indications, has proven to be more useful for the treatment of a variety of hyperkinetic movement disorders. These disorders include neurological diseases characterized by abnormal involuntary movements such as chorea associated with Huntington's disease, tics in Tourette's syndrome, dyskinesias and dystonias in tardive dyskinesia, also primary dystonias and myoclonus. This review will include and discuss studies published during the period of 1960-2006 regarding the clinical efficacy and tolerability of TBZ in Huntington's disease (HD). It will also review the chemistry, pharmacokinetics and dynamics of the drug and its mechanism of action compared to that of reserpine, the only similar compound. This review emphasizes the advantage of TBZ over dopamine-depleting compounds used in the treatment of chorea and reveals its clinical efficacy and side effects.

Citing Articles

Protective Effects of Antcin H Isolated from Antrodia cinnamomea Against Neuroinflammation in Huntington's Disease via NLRP3 Inflammasome Inhibition.

Chang Y, Chen C, Chen Y, Wu M, Lin T, Hua K J Neuroimmune Pharmacol. 2024; 20(1):1.

PMID: 39621196 DOI: 10.1007/s11481-024-10161-7.

Efficacy and Safety of Tetrabenazine in Reducing Chorea and Improving Motor Function in Individuals With Huntington's Disease: A Systematic Review.

Vadlamani N, Ibrahimli S, Khan F, Castillo J, Amaravadi K, Nalisetty P Cureus. 2024; 16(10):e71476.

PMID: 39544557 PMC: 11560395. DOI: 10.7759/cureus.71476.

Neurotransmitter recognition by human vesicular monoamine transporter 2.

Im D, Jormakka M, Juge N, Kishikawa J, Kato T, Sugita Y Nat Commun. 2024; 15(1):7661.

PMID: 39284862 PMC: 11405867. DOI: 10.1038/s41467-024-51960-z.

Heavy Metal Interactions with Neuroglia and Gut Microbiota: Implications for Huntington's Disease.

Tizabi Y, Bennani S, El Kouhen N, Getachew B, Aschner M Cells. 2024; 13(13.

PMID: 38994995 PMC: 11240758. DOI: 10.3390/cells13131144.

Neurotoxicology of dopamine: Victim or assailant?.

Bucher M, Dicent J, Hospital C, Miller G Neurotoxicology. 2024; 103:175-188.

PMID: 38857676 PMC: 11694735. DOI: 10.1016/j.neuro.2024.06.001.

References

Tarsy . Tardive Dyskinesia. Curr Treat Options Neurol. 2000; 2(3):205-214. DOI: 10.1007/s11940-000-0003-4. View

Raja M . Managing antipsychotic-induced acute and tardive dystonia. Drug Saf. 1998; 19(1):57-72. DOI: 10.2165/00002018-199819010-00005. View

Faulstich M, Carnrike Jr C, Williamson D . Blepharospasm and Meige syndrome: a review of diagnostic, aetiological and treatment approaches. J Psychosom Res. 1985; 29(1):89-94. DOI: 10.1016/0022-3999(85)90012-1. View

Fahn S . A therapeutic approach to tardive dyskinesia. J Clin Psychiatry. 1985; 46(4 Pt 2):19-24. View

Scherman D, Henry J . Acido-basic properties of the catecholamine uptake inhibitors tetrabenazine and dihydrotetrabenazine. Biochimie. 1982; 64(10):915-21. DOI: 10.1016/s0300-9084(82)80354-4. View

Moss J, Stewart D . Iatrogenic parkinsonism in Huntington's chorea. Can J Psychiatry. 1986; 31(9):865-6. DOI: 10.1177/070674378603100916. View

GILLIGAN B, Wodak J, Veale J, Munro O . Tetrabenazine in the treatment of extrapyramidal dyskinesias. Med J Aust. 1972; 2(19):1054-6. DOI: 10.5694/j.1326-5377.1972.tb103717.x. View

Jankovic J . Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982; 11(1):41-7. DOI: 10.1002/ana.410110108. View

Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S . Tetrabenazine treatment in movement disorders. Clin Neuropharmacol. 2004; 27(5):230-3. DOI: 10.1097/01.wnf.0000136892.24629.96. View

10.

Duran E, Chacon J . [Spasmodic torticollis and vertebral hemangioma]. Rev Neurol. 2001; 32(1):60-2. View

11.

Quinn G, Shore P, Brodie B . Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther. 1959; 127:103-9. View

12.

Mikkelsen B . Tolerance of tetrabenazine during long-term treatment. Acta Neurol Scand. 1983; 68(1):57-60. DOI: 10.1111/j.1600-0404.1983.tb04816.x. View

13.

Swash M, Roberts A, Zakko H, HEATHFIELD K . Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry. 1972; 35(2):186-91. PMC: 494034. DOI: 10.1136/jnnp.35.2.186. View

14.

van Vugt J, Siesling S, Vergeer M, van der Velde E, Roos R . Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry. 1997; 63(1):35-9. PMC: 2169648. DOI: 10.1136/jnnp.63.1.35. View

15.

Jankovic J, Beach J . Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997; 48(2):358-62. DOI: 10.1212/wnl.48.2.358. View

16.

SATTES H, Hase E . [THE TREATMENT OF EXTRAPYRAMIDAL HYPERKINESIAS WITH SPECIAL REFERENCE TO HUNTINGTON'S CHOREA]. Psychiatr Neurol Neurochir. 1964; 67:289-98. View

17.

McLellan D, Chalmers R, Johnson R . A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet. 1974; 1(7848):104-7. DOI: 10.1016/s0140-6736(74)92338-1. View

18.

Kidd D, McLellan D . Self-poisoning with tetrabenazine. Br J Clin Pract. 1972; 26(4):179-80. View

19.

Gonzalez A, Walther D, Pazos A, Uhl G . Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res. 1994; 22(1-4):219-26. DOI: 10.1016/0169-328x(94)90050-7. View

20.

Erickson J, Schafer M, Bonner T, Eiden L, Weihe E . Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1996; 93(10):5166-71. PMC: 39426. DOI: 10.1073/pnas.93.10.5166. View